US2021062170A1PendingUtilityA1

Site-specific enzymes and methods of use

63
Assignee: POSEIDA THERAPEUTICS INCPriority: Nov 16, 2012Filed: Nov 16, 2020Published: Mar 4, 2021
Est. expiryNov 16, 2032(~6.3 yrs left)· nominal 20-yr term from priority
C07K 14/195C12N 9/22
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides polypeptides related t Ralstonia proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A fusion protein comprising
 (a) at least one amino acid sequence having a sequence at least 95% identical to the sequence of   LSTEQVVAIASX 1 X 2 GGKQALEAVKAQLLVLRAAPYE (SEQ ID NO: 1), wherein X 1 X 2  comprises a repeat variable diresidue (RVD), and wherein the RVD consists of SI, SN, SH, NP, NH, NT, NK, ND, HN, HY, HD, HH, RN, RS, NG or GS, and wherein the amino acids recited at positions 2 and 3 of SEQ ID NO: 1 are unchanged;   and   (b) an effector domain,   wherein the effector domain comprises a nuclease, a nickase, a transcriptional activator, a transcriptional repressor, a methyltransferase, a deacetylase or any functional fragment thereof and   wherein the effector domain is neither isolated nor derived from a  Ralstonia  TALEN.   
     
     
         2 . The fusion protein of  claim 1 , wherein the at least one amino acid sequence of (a) or the second amino acid sequence comprises the amino acid sequence of SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, or SEQ ID NO:19. 
     
     
         3 . The fusion protein of  claim 1 , wherein the effector domain comprises at least one nuclease. 
     
     
         4 . The fusion protein of  claim 1 , wherein the nuclease comprises an endonuclease. 
     
     
         5 . The fusion protein of  claim 4 , wherein the endonuclease comprises a Fok I endonuclease. 
     
     
         6 . The fusion protein of  claim 5 , wherein the endonuclease comprises an I-SceI endonuclease. 
     
     
         7 . The fusion protein of  claim 1 , wherein the effector domain comprises a zinc-finger nuclease.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.